CAN017 / Canwell Biotech - LARVOL DELTA

A novel StarLinkerTM-based, CLDN18.2/PD-L1 bispecific dual-payload ADC (CAN017) overcomes tumor heterogeneity (AACR 2026) - "The CLDN18.2/PD-L1 bispecific dual-payload ADC (CAN017), enabled by the StarLinkerTM technology, shown superior antitumoral effects in various preclinical tumor models. Coupling with its preliminary excellent DMPK and safety profiles, it provides a strong path to become a potent next-generation ADC for the treatments of advanced solid tumors, particularly pancreatic and GI cancers."

ADC • Bispecific • Heterogeneity • Gastric Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • CLDN18 • PD-L1